Biolumpivaxin

On May 14, 2025, Andhra Pradesh Chief Minister N. Chandrababu Naidu launched a novel animal vaccine called Biolumpivaxin for Lumpy Skin Disease (LSD) in animals.
This initiative is not only a pioneering step towards the control of Lumpy Skin Disease (LSD) but is also extremely important for the state’s livestock development target (20% growth) and long-term sustainability of the dairy industry.

About Biolumpivaxin

Development & Testing: Developed by Biovet, a subsidiary of Biotech, in collaboration with the Indian Council of Agricultural Research (ICAR).
- It was approved by the Central Drugs Standard Control Organization (CDSCO) in February 2025.
Key Features : It is the world’s first DIVA (Differentiating Infected from Vaccinated Animals) marker vaccine, which allows scientifically distinguishing infected animals from vaccinated animals.
- It can be administered once a year to cattle and buffaloes of all ages.
- It develops full immunity in 3–4 weeks.

What it is : LSD is a viral infectious disease that mainly affects cattle like cows and buffaloes.
- It causes formation of skin lumps all over the body, fever, swollen lymph nodes, reduced milk production and difficulty in movement.
Transmission : LSD virus is transmitted primarily through vector bites, which include mosquitoes, ticks and other biting insects.
Impact: Animals infected with this disease suffer heavy economic losses, which has a serious impact on farmers and the country's dairy industry.
First case: Its first case was recorded in Zambia (Africa) in the year 1929.
- It is a Transboundary Animal Disease (TAD) listed by FAO.
Situation in India: The first case was recorded in the year 2019.
Severe outbreak in 2022: Lakhs of cattle infected and death of more than 1 lakh animals confirmed in states like Rajasthan, Gujarat, Punjab, Haryana, Uttar Pradesh, Maharashtra etc.